BridgeBio Oncology Therapeutics (BBOT) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, gaining 53.0% versus a loss of 71.6%. BridgeBio Oncology Therapeutics is the larger company by market cap ($265.4 million vs $259.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | ZNTL |
|---|---|---|
| Share price | $3.31 | $2.64 |
| Market cap | $265.38M | $259.04M |
| 1-day change | -3.22% | +5.18% |
| YTD return | -72.68% | +85.93% |
| 1-year return | -71.56% | +53.05% |
| 5-year return | — | -96.65% |
| EPS (TTM) | $-0.07 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.87 | $6.95 |
| 52-week low | $3.27 | $1.21 |
| Distance from 52-week high | -77.74% | -62.01% |
| Analyst consensus | none | buy |
| Avg. price target upside | +641.69% | +177.65% |
| Average volume | 468.94K | 1.21M |
| Shares outstanding | 80.17M | 98.12M |
| Employees | 88 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed BBOT by 124.6 percentage points over the past year.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
BBOT vs ZNTL FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Zentalis Pharmaceuticals?
BridgeBio Oncology Therapeutics (BBOT) is larger, with a market capitalization of $265.38M compared with $259.04M for Zentalis Pharmaceuticals (ZNTL).
Which stock has performed better over the past year, BBOT or ZNTL?
ZNTL returned +53.05% over the past 12 months, compared with -71.56% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Oncology Therapeutics and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.